VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN

Carla M Nester; Andrew S Bomback; Gema Ariceta; Yahsou Delmas; Bradley P Dixon; Daniel P Gale; Larry A Greenbaum; Seung Hyeok Han; Nicole Isbel; Christoph Licht; Antonio Mastrangelo; Masashi Mizuno; Maria Izabel Neves De Holanda; Matthew C Pickering; Giuseppe Remuzzi; Nicole Van De Kar; Marina Vivarelli; Patrick D Walker; Dean Wallace; Daniel Zecher; Li Li; Zhongshen Wang; Luis López Lázaro; Johan Szamosi; Fadi Fakhouri

doi:10.1016/j.imbio.2025.153039

Home
Search
VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN

1
https://doi.org/10.1016/j.imbio.2025.153039

VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN

Jul 1, 2025
Immunobiology
Carla M Nester +24 more

Listen

Abstract
Literature Map
Citations
Similar Papers

Abstract

VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN